KyungMann Kim
Overview
Explore the profile of KyungMann Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
2971
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rahafrooz M, Elbers D, Gopal J, Ren J, Chan N, Yildirim C, et al.
J Am Med Inform Assoc
. 2024 Dec;
32(2):349-356.
PMID: 39671451
Objective: Event capture in clinical trials is resource-intensive, and electronic medical records (EMRs) offer a potential solution. This study develops algorithms for EMR-based death and hospitalization capture and compares them...
2.
Knutson Sinaise M, Zaborek J, Kim K, Lauver D, McBride P, Pearson J, et al.
BMC Cardiovasc Disord
. 2024 Nov;
24(1):636.
PMID: 39538139
Background: Hypertension is a major risk factor for heart disease, heart failure and stroke. Lifestyle changes are recommended as first-line treatment for management of high blood pressure for young adults,...
3.
Chang J, McQuinn D, Hyun M, Kim K, Kenkre V, Rajguru S, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Oct;
25(3):188-198.
PMID: 39477701
Introduction: Obinutuzumab is hypothesized to improve progression-free survival (PFS) combined with bendamustine induction in mantle cell lymphoma (MCL). Measurable-residual disease (MRD) testing may predict benefit from maintenance therapy. Methods: Adults...
4.
Jagodinsky J, Vera J, Jin W, Shea A, Clark P, Sriramaneni R, et al.
Sci Transl Med
. 2024 Sep;
16(765):eadk0642.
PMID: 39292804
Radiation therapy (RT) activates multiple immunologic effects in the tumor microenvironment (TME), with diverse dose-response relationships observed. We hypothesized that, in contrast with homogeneous RT, a heterogeneous RT dose would...
5.
Downs T, Bailey H, Lozar T, Schmitz N, Green H, Scarlett C, et al.
Cancer Prev Res (Phila)
. 2024 Aug;
18(1):31-39.
PMID: 39187984
We performed a clinical trial in patients with non-muscle-invasive (NMI) urothelial cancer randomized (2:1) to the EGFR tyrosine kinase inhibitor erlotinib or placebo (either orally once weekly × 3 doses...
6.
Kerr C, Sheehan-Klenk J, Grudzinski J, Adam D, Nguyen T, Ferreira C, et al.
bioRxiv
. 2024 Jul;
PMID: 39071353
Teaser: This study describes the time course and nature of tumor immunomodulation by radiopharmaceuticals with differing physical properties.
7.
Dehghani P, Srivatsav V, Vardeny O, Grewal J, Opotowsky A, Muhll I, et al.
JACC Adv
. 2024 Jun;
3(4):100897.
PMID: 38939662
Background: Adult congenital heart disease (ACHD) patients have significant morbidity and rise in cardiac admissions. Their outcome with high-dose influenza vaccination is unknown in comparison to those without ACHD. Objectives:...
8.
Chang J, Wang T, Kim K, Folstad M, Endres M, Howard M, et al.
Leuk Lymphoma
. 2024 Jun;
65(10):1456-1464.
PMID: 38856101
Lenalidomide (LEN) and rituximab (RTX) have independently improved progression-free survival (PFS) in CLL, leading to interest in use of LEN + RTX (R2) following induction chemoimmunotherapy. Patients with previously untreated...
9.
Peikert A, Claggett B, Udell J, Joseph J, Hegde S, Kim K, et al.
JAMA Cardiol
. 2024 Apr;
9(6):574-581.
PMID: 38583091
Importance: High-dose trivalent compared with standard-dose quadrivalent influenza vaccine did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations in patients with high-risk cardiovascular disease in the INVESTED trial. Whether humoral...
10.
Jin W, Jagodinsky J, Vera J, Clark P, Zuleger C, Erbe A, et al.
Cell Rep
. 2023 Dec;
42(12):113556.
PMID: 38096050
We report an in situ vaccination, adaptable to nearly any type of cancer, that combines radiotherapy targeting one tumor and intratumoral injection of this site with tumor-specific antibody and interleukin-2...